Similar to the BHGZD formula, the two-BAC combination treatment of MG and CA may exert satisfying therapeutic efficacy on both in vivo and in vitro experiments via regulating TLR4/PI3K/AKT/NFκB signaling, which plays a vital role in synovial inflammation, cartilage degradation, and bone erosion by regulating inflammation response, immune disorder cells, and pyroptosis (37, 49–52). The gene discussed is NFKB1; the disease is myasthenia gravis.